Mounjaro has become one of the most searched weight-loss and diabetes medications in the world, and increasingly in India, where it launched in March 2025. As GLP-1 drugs have moved from niche diabetes treatments to mainstream weight-management tools, a natural question has followed: what exactly is Mounjaro, and does it outperform Ozempic and Wegovy, the two semaglutide-based drugs that came before it?
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide, an injectable prescription medicine made by Eli Lilly. It was first approved by the U.S. Food and Drug Administration in 2022 for adults with type 2 diabetes, used alongside diet and exercise to improve blood sugar control. Mounjaro belongs to a class of medicines known as GLP-1 drugs, though technically it goes a step further than earlier options in this category.
Most older GLP-1 weight loss drugs, including Ozempic and Wegovy, work by activating a single hormone receptor called GLP-1, which slows digestion, increases insulin release, and signals fullness to the brain. Mounjaro is a dual agonist: it activates both the GLP-1 receptor and a second receptor called GIP (glucose-dependent insulinotropic polypeptide). This two-pathway mechanism is the central reason tirzepatide has produced some of the strongest weight-loss results seen in this drug class to date.
Mounjaro for Diabetes, and the Weight Loss Connection
Mounjaro’s original and primary approval is for type 2 diabetes management. However, because tirzepatide also produces substantial appetite reduction and weight loss as a side effect of its mechanism, Eli Lilly developed a separate, identically formulated drug called Zepbound, specifically approved for chronic weight management. Mounjaro itself is not officially approved as a weight-loss drug, though it is sometimes prescribed off-label for that purpose, similar to how Ozempic is approved for diabetes but is also used off-label for weight loss, while Wegovy is semaglutide’s dedicated weight-management version.
Mounjaro vs Ozempic vs Wegovy: Comparing Weight Loss Results
This is where the head-to-head comparison matters most. In clinical trials, tirzepatide (the active ingredient in Mounjaro and Zepbound) produced average weight loss of around 15 to 22.5 percent of body weight at higher doses over roughly 72 weeks. Semaglutide (the active ingredient in Ozempic and Wegovy) produced average weight loss in the range of 15 to 17 percent over similar trial durations. A head-to-head trial directly comparing tirzepatide against semaglutide found tirzepatide produced greater reductions in both blood sugar and body weight at every dose studied.
That said, cross-trial comparisons should be read with some caution, since trial populations, durations, and dosing protocols differ. What the evidence does support fairly consistently is that tirzepatide’s dual-receptor mechanism tends to produce somewhat greater average weight loss than semaglutide-based drugs, making Mounjaro (and Zepbound) generally regarded as the more potent option currently available in this category, though individual results vary considerably from person to person.
It’s worth noting that Mounjaro weight loss results in clinical trials were achieved alongside a reduced-calorie diet and increased physical activity, not from the injection alone. Doctors and researchers generally describe these drugs as tools that make it easier to stick to a calorie deficit and reduce food cravings, rather than a replacement for basic lifestyle changes.
Mounjaro Side Effects and Safety Considerations
Like other GLP-1 drugs, Mounjaro’s most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach discomfort, particularly during the first weeks of treatment or when the dose is increased. These effects often ease as the body adjusts.
More seriously, Mounjaro carries an FDA boxed warning, the agency’s strongest safety warning, for a risk of thyroid C-cell tumors observed in animal studies; it is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other reported risks include acute pancreatitis, gallbladder problems, and low blood sugar when combined with other diabetes medications. Full prescribing details are available in Mounjaro’s official FDA label. Anyone considering Mounjaro, for diabetes or otherwise, should discuss their full medical history with a doctor before starting treatment.
Mounjaro Price in India and Availability
Mounjaro’s availability in India has expanded significantly since its March 2025 launch by Eli Lilly. It is sold as a Schedule H prescription medicine, meaning it legally requires a doctor’s prescription and cannot be purchased over the counter. It is available in both prefilled KwikPens and vials across major Indian pharmacy chains and hospital pharmacies.
On pricing, Mounjaro in India generally costs between roughly ₹13,000 and ₹27,500 per month depending on the prescribed dose, with the starting 2.5 mg dose priced lowest and the maximum 15 mg dose priced highest. Because tirzepatide remains under patent protection in India for several more years, no generic version currently exists, unlike semaglutide, whose Indian patent has already expired and which now has generic competitors on the market. Health insurance coverage for Mounjaro in India remains limited, particularly when prescribed purely for weight loss rather than diagnosed diabetes.
GLP-1 Drugs for Weight Loss: How to Think About the Options
With multiple GLP-1 weight loss drugs now available, including Ozempic, Wegovy, Mounjaro, and Zepbound, the “best” option isn’t universal. It depends on a person’s diagnosis (diabetes versus obesity), how their body responds to each medication, side-effect tolerance, and, in India specifically, cost and availability, since none of these injectable GLP-1 drugs are inexpensive and coverage varies widely.
What the current evidence does suggest is that tirzepatide-based drugs like Mounjaro tend to produce somewhat greater average weight loss than semaglutide-based drugs like Ozempic and Wegovy, largely due to their dual-hormone mechanism. But GLP-1 drugs for diabetes and weight loss alike are prescription medications with real side effects and safety warnings, not casual lifestyle products, and any decision about starting or switching between them should be made with a qualified doctor rather than based on marketing claims or social media trends.
This article is for general informational purposes and does not constitute medical advice. Consult a qualified healthcare provider before starting, stopping, or switching any prescription medication.